Accès gratuit
Numéro
Med Sci (Paris)
Volume 25, Mai 2009
Biotechnologies et innovation thérapeutique
Bioproduction
Cellules souches
Biologie synthétique
Page(s) 32 - 38
Section M/S revues
DOI https://doi.org/10.1051/medsci/2009252s32
Publié en ligne 15 février 2009
  1. Thomson JA, Itskovitz-Eldor J, Shapiro SS, et al. Embryonic stem cell lines derived from human blastocysts. Science 1998; 282 : 1145–7.
  2. Smith AG. Embryo-derived stem cells: of mice and men. Annu Rev Cell Dev Biol 2001; 17 : 435–62.
  3. Gorba T, Allsopp TE. Pharmacological potential of embryonic stem cells. Pharmacol Res 2003; 47 : 269–78.
  4. McNeish J. Embryonic stem cells in drug discovery. Nat Rev Drug Discov 2004; 3 : 70–80.
  5. Cezar GG. Can human embryonic stem cells contribute to the discovery of safer and more effective drugs ? Curr Opin Chem Biol 2007; 11 : 405–9.
  6. McNeish JD. Stem cells as screening tools in drug discovery. Curr Opin Pharmacol 2007; 7 : 515–20.
  7. Sartipy P, Björquist P, Strehl R, Hyllner J. The application of human embryonic stem cell technologies to drug discovery. Drug Discovery Today 2007; 12 : 688–99.
  8. Ameen C, Strehl R, Bjorquist P, et al. Human embryonic stem cells: current technologies and emerging industrial applications. Crit Rev Oncol Hematol 2008; 65 : 54–80.
  9. Wilson PG, Cherry JJ, Schwamberger S, et al. An SMA project report: neural cell-based assays derived from human embryonic stem cells. Stem Cells Dev 2007; 16 : 1027–41.
  10. Coulombel L, De Vos J, Puceat M. FISH-ESC : premier colloque international sur la recherche dédiée aux cellules souches embryonnaires humaines. Med Sci (Paris) 2008; 24 : 419–26.
  11. Pickering SJ, Braude PR, Patel M, et al. Preimplantation genetic diagnosis as a novel source of embryos for stem cell research. Reprod Biomed (Online) 2003; 7 : 353–64.
  12. Verlinsky Y, Strelchenko N, Kukharenko V,et al. Human embryonic stem cell lines with genetic disorders. Reprod Biomed (Online) 2005; 10 : 105–10.
  13. Mateizel I, De Temmerman N, Ullmann U, et al. Derivation of human embryonic stem cell lines from embryos obtained after IVF and after PGD for monogenic disorders. Hum Reprod 2006; 21 : 503–11.
  14. Eiges R, Urbach A, Malcov M, et al. Developmental study of fragile X syndrome using human embryonic stem cells derived from preimplantation genetically diagnosed embryos. Cell Stem Cell 2007; 1 : 568–77.
  15. Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007; 131 : 861–72.
  16. Yu J, Vodyanik MA, Smuga-Otto K, et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 2007; 318 : 1917–20.
  17. Coulombel L. Cellules iPS humaines : déjà ! Med Sci (Paris) 2008; 24 : 102–4.
  18. Rigamonti D, Bolognini D, Mutti C, et al. Loss of huntingtin function complemented by small molecules acting as repressor element 1/neuron restrictive silencer element silencer modulators. J Biol Chem 2007; 282 : 24554–62.
  19. Leone S, Mutti C, Kazantsev A, et al. SAR and QSAR study on 2-aminothiazole derivatives, modulators of transcriptional repression in Huntington’s disease. Bioorg Med Chem 2008; 16 : 5695–703.
  20. Spielmann H, Pohl I, Doering B, et al. The embryonic stem cell test, an in vitro embryotoxicity test using two permanent mouse cell lines: 3T3 fibroblasts and embryonic stem cells. In Vitro Toxicology 1997; 199–227
  21. Genschow E, Spielmann H, Scholz G, et al. Validation of the embryonic stem cell test in the international ECVAM validation study on three in vitro embryotoxicity tests. Altern Lab Anim 2004; 32 : 209–44.
  22. Adler S, Pellizzer C, Hareng L, et al. First steps in establishing a developmental toxicity test method based on human embryonic stem cells. Toxicol In Vitro 2008; 22 : 200–11.
  23. Hareng L, Pellizzer C, Bremer S, et al. The integrated project ReProTect: a novel approach in reproductive toxicity hazard assessment. Reprod Toxicol 2005; 20 : 441–52.
  24. Wilkening S, Stahl F, Bader A. Comparison of primary human hepatocytes and hepatoma cell line Hepg2 with regard to their biotransformation properties. Drug Metab Dispos 2003; 31 : 1035–42.
  25. Agarwal S, Holton KL, Lanza R. Efficient Differentiation of functional hepatocytes from human embryonic stem cells. Stem Cells 2008 (online).
  26. Hay DC, Zhao D, Fletcher J, et al. Efficient differentiation of hepatocytes from human embryonic stem cells exhibiting markers recapitulating liver development in vivo. Stem Cells 2008; 26 : 894–902.
  27. Soderdahl T, Kuppers-Munther B, Heins N, et al. Glutathione transferases in hepatocyte-like cells derived from human embryonic stem cells. Toxicol In Vitro 2007; 21 : 929–37.
  28. Pouton CW, and Haynes JM. Embryonic stem cells as a source of models for drug discovery. Nat Rev Drug Discov 2007; 6 : 605–16.
  29. Terstegge S, Laufenberg I, Pochert J, et al. Automated maintenance of embryonic stem cell cultures. Biotechnol Bioeng 2007; 96 : 195–201.
  30. Thomson H. Bioprocessing of embryonic stem cells for drug discovery. Trends Biotechnol 2007; 25 : 224–30.
  31. Peschanski M. Cellules souches : l’heure venue du changement d’échelle. Med Sci (Paris) 2008; 24 : 335–8.
  32. Pouton CW, and Haynes JM. Pharmaceutical applications of embryonic stem cells. Adv Drug Deliv Rev 2005; 57 : 1918–34.
  33. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates ? Nat Rev Drug Discov 2004; 3 : 711–5.
  34. Bremer S, Pellizzer C, Hoffmann S, et al. The development of new concepts for assessing reproductive toxicity applicable to large scale toxicological programmes. Curr Pharm Des 2007; 13 : 3047–58.
  35. Trounson A. The production and directed differentiation of human embryonic stem cells. Endocrinol Rev 2006; 27 : 208–19.
  36. Reppel M, Pillekamp, Brockmeier K,et al. The electrocardiogram of human embryonic stem cell-derived cardiomyocytes.J Electrocardiol 2005; 38 (suppl 4) : 166–70.
  37. Stemina presents at tri-molecular conference. Présentation téléchargeable sur le site web de la société Stemina. http://www.stemina.com/

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.